A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01472250|
Recruitment Status : Completed
First Posted : November 16, 2011
Last Update Posted : May 9, 2017
This is a multi-center, prospective and observational clinical study. Eligible patients will accept generalized chemotherapy according to the investigator's assessment. Information related to the treatment, including medication, disease condition, expenses, etc. will be periodically collected. Follow-up at 2-month intervals will be periodically performed to continually collect information about the disease progression, subsequent treatment and survival until death or completion of the study.
Recruited patients will fill out questionnaires about quality of life before initiation of treatment, at Cycle 3 and completion of first-line treatment.
|Condition or disease||Intervention/treatment|
|Advanced Gastric Cancer||Drug: Clinical chemo-drugs|
|Study Type :||Observational|
|Actual Enrollment :||498 participants|
|Official Title:||A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||July 2016|
Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
Drug: Clinical chemo-drugs
Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:
Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel
- chemotherapy regimen [ Time Frame: 2 months ]To evaluate the treatment model (singel or doublet or triplet chemotherapy)of patients with advanced gastric cancer in China
- overall survival [ Time Frame: 2 months ]OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 2 months till death or lost
- quality of life [ Time Frame: 6 weeks ]To evaluate the quality of life before and after chemotherapy of Chinese patients in real clinical practice
- treatment expense [ Time Frame: 2 months ]To evaluate the treatment expense of first-line treatment of Chinese patients with advanced gastric cancer in real clinical practice
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01472250
|Beijing, Beijing, China, 100142|